Overview

Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa

Status:
Completed

Trial end date:
2019-11-06

Target enrollment:

Participant gender:

Summary

The primary objective of this study was to evaluate the efficacy of roxadustat compared to darbepoetin alfa in the treatment of anemia in nondialysis-dependent chronic kidney disease (NDD CKD) participants.

Phase:

Phase 3

Details

Lead Sponsor:

Astellas Pharma Europe B.V.

Collaborator:

FibroGen

Treatments:

Darbepoetin alfa